Antifibrotic therapies--emerging biomarkers as treatment end points.
The emergence of novel pharmacologic therapies for hepatic fibrosis holds promise for the management of this condition. Furthermore, novel, biological indices-in addition to liver biopsy-may improve our ability to assess the unique pharmacological effects generated by these agents. This article will attempt to highlight the potential for emerging biomarkers to serve as end points in clinical studies that target salient features of hepatic fibrogenesis.
Talwalkar
Jayant A
JA
Center for Advanced Imaging Research, Miles and Shirley Fiterman Center for Digestive Diseases, Mayo Clinic, Rochester, MN 55905, USA. talwalkar.jayant@mayo.edu
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000818:Animals; D015415:Biomarkers / Q000378:metabolism*; D001706:Biopsy; D018450:Disease Progression; D016326:Extracellular Matrix Proteins / Q000378:metabolism*; D006801:Humans; D008103:Liver Cirrhosis / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D011379:Prognosis
D020533:Angiogenesis Inhibitors; D015415:Biomarkers; D016326:Extracellular Matrix Proteins